| Fosnetupitant chloride hydrochloride; palonosetron hydrochloride | HELSINN | ||
| 235 mg/20 mL and 0.25mg/20 mL ; Solution, Intravenous |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
| None | None | ||
| None | None | ||
| AKYNZEO for injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. | |||
|
Yes
| |||
| Akynzeo | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| ***** ****** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******** ********** *** ******** ************* **** ** *-(*-(*-(*,*-***(***************)******)-*,*-*******************)-*-(*-*****)*******-*-**)-*-******-*-((************)******)*********-*-***-(*************) *** ************ ************* ** *********** **** ************* ** * ********** ******** ********* | *************** ******** ********** ************ ** ************* | *********** ************* *** *** ********* ** ****** | ************ *** ******* *** ******** ********* ******** ****** *** ******** | ************* ******** ************* ****** ******** ********* | *********** *-****** ********* ****** ****-****** ****** | ******* ** ******** ****** | ************ *** ******* *** ******** ********* ******** ****** *** ******** | *-(*-(*-(*,*-***(***************)******)-*,*-*******************)-*-(*-*****)*******-*-**)-*-******-*-((************)******)*********-*-*** ** * ********** ******** ********* | *********** ************* *** *** ********* ** ****** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** ****** | *** \ ********* | *** **, **** | ******* | **** | ******* *** **** *** *** **** |
| Fosnetupitant chloride hydrochloride; palonosetron hydrochloride | None | ||
| 300MG;0.5MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| AKYNZEO is a combination of palonosetron, a serotonin-3 (5-HT3) receptor antagonist, and netupitant or fosnetupitant, substance P/neurokinin-1 (NK-1) receptor antagonists: palonosetron prevents nausea and vomiting during the acute phase and netupitant/fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. | |||
|
Yes
| |||
| Akynzeo | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||||||||
| ************ *** ******* *** ******** ********* ******** ****** *** ******** | ************ *** ******* *** ******** ********* ******** ****** *** ******** | ************ *** ******* *** ******** ********* ******** ****** *** ******** | ************ *** ******* *** ******** ********* ******** ****** *** ******** | ************ *** ******* *** ******** ********* ******** ****** *** ******** | *********** ***** ** ** **-* ********** | *********** ***** ** ** **-* ********** | *********** ***** ** ** **-* ********** | ************ *** ******* *** ******** ********* ******** ****** *** ******** | *********** ***** ** ** **-* ********** | ************ *** ******* *** ******** ********* ******** ****** *** ******** | ************ *** ******* *** ******** ********* ******** ****** *** ******** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|